Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis (Review)
- Authors:
- Hiroshi Kobayashi
- Shogo Imanaka
- Hiroshi Shigetomi
-
Affiliations: Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara 634‑8522, Japan - Published online on: January 11, 2022 https://doi.org/10.3892/ol.2022.13200
- Article Number: 80
-
Copyright: © Kobayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Kurman RJ: Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 24 (Suppl 10):x16–x21. 2013. View Article : Google Scholar : PubMed/NCBI | |
Jaganjac M, Milkovic L, Sunjic SB and Zarkovic N: The NRF2, Thioredoxin, and glutathione system in tumorigenesis and anticancer therapies. Antioxidants (Basel). 9:11512020. View Article : Google Scholar : PubMed/NCBI | |
Gram M and Åkerström B: Editorial: Biomarkers of oxidative stress. Front Physiol. 11:3382020. View Article : Google Scholar : PubMed/NCBI | |
Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H and LLeonart ME: Oxidative stress and cancer: An overview. Ageing Res Rev. 12:376–390. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang T, Shigdar S, Gantier MP, Hou Y, Wang L, Li Y, Shamaileh HA, Yin W, Zhou SF, Zhao X and Duan W: Cancer stem cell targeted therapy: Progress amid controversies. Oncotarget. 6:44191–44206. 2016. View Article : Google Scholar : PubMed/NCBI | |
Meng Y, Fan XY, Yang LJ, Xu BQ, He D, Xu Z, Wu D, Wang B, Cui HY, Wang SJ, et al: Detachment activated CyPA/CD147 induces cancer stem cell potential in non-stem breast cancer cells. Front Cell Dev Biol. 8:5438562020. View Article : Google Scholar : PubMed/NCBI | |
Mvunta DH, Miyamoto T, Asaka R, Yamada Y, Ando H, Higuchi S, Ida K, Kashima H and Shiozawa T: SIRT1 regulates the chemoresistance and invasiveness of ovarian carcinoma cells. Transl Oncol. 10:621–631. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shimizu T, Inoue K, Hachiya H, Shibuya N, Shimoda M and Kubota K: Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas. J Gastroenterol. 49:1324–1332. 2014. View Article : Google Scholar : PubMed/NCBI | |
Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM, Mori K, Sadighi Akha AA, Raden D and Kaufman RJ: Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol. 4:e3742006. View Article : Google Scholar : PubMed/NCBI | |
Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI | |
Hayes JD, Dinkova-Kostova AT and Tew KD: Oxidative stress in cancer. Cancer Cell. 38:167–197. 2020. View Article : Google Scholar : PubMed/NCBI | |
Narayanan D, Ma S and Özcelik D: Targeting the redox landscape in cancer therapy. Cancers (Basel). 12:17062020. View Article : Google Scholar : PubMed/NCBI | |
Schiliro C and Firestein BL: Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 10:10562021. View Article : Google Scholar : PubMed/NCBI | |
Chen L, Zhang Z, Hoshino A, Zheng HD, Morley M, Arany Z and Rabinowitz JD: NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism. Nat Metab. 1:404–415. 2019. View Article : Google Scholar : PubMed/NCBI | |
Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M and Yang X: p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol. 13:310–316. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nakashima C, Yamamoto K, Fujiwara-Tani R, Luo Y, Matsushima S, Fujii K, Ohmori H, Sasahira T, Sasaki T, Kitadai Y, et al: Expression of cytosolic malic enzyme (ME1) is associated with disease progression in human oral squamous cell carcinoma. Cancer Sci. 109:2036–2045. 2018. View Article : Google Scholar : PubMed/NCBI | |
Liu X and Gong Y: Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomark Res. 7:222019. View Article : Google Scholar : PubMed/NCBI | |
Jiang P, Du W and Wu M: Regulation of the pentose phosphate pathway in cancer. Protein Cell. 5:592–602. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pramono AA, Rather GM, Herman H, Lestari K and Bertino JR: NAD- and NADPH-contributing enzymes as therapeutic targets in cancer: An overview. Biomolecules. 10:3582020. View Article : Google Scholar : PubMed/NCBI | |
Gupta RK, Patel AK, Shah N, Chaudhary AK, Jha UK, Yadav UC, Gupta PK and Pakuwal U: Oxidative stress and antioxidants in disease and cancer: A review. Asian Pac J Cancer Prev. 15:4405–4409. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kitamura H and Motohashi H: NRF2 addiction in cancer cells. Cancer Sci. 109:900–911. 2018. View Article : Google Scholar : PubMed/NCBI | |
Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, Shyr C, Wakabayashi N, Kensler TW, Wasserman WW and Biswal S: Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38:5718–5734. 2010. View Article : Google Scholar : PubMed/NCBI | |
Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M and Motohashi H: Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 22:66–79. 2012. View Article : Google Scholar : PubMed/NCBI | |
Tanaka G, Inoue K, Shimizu T, Akimoto K and Kubota K: Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells. Cancer Med. 5:2544–2557. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wang YY, Chen J, Liu XM, Zhao R and Zhe H: Nrf2-Mediated metabolic reprogramming in cancer. Oxid Med Cell Longev. 2018:93040912018. View Article : Google Scholar : PubMed/NCBI | |
Dodson M, de la Vega MR, Cholanians AB, Schmidlin CJ, Chapman E and Zhang DD: Modulating NRF2 in disease: Timing is everything. Annu Rev Pharmacol Toxicol. 59:555–575. 2019. View Article : Google Scholar : PubMed/NCBI | |
Ma Q: Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 53:401–426. 2013. View Article : Google Scholar : PubMed/NCBI | |
Menegon S, Columbano A and Giordano S: The dual roles of NRF2 in cancer. Trends Mol Med. 22:578–593. 2016. View Article : Google Scholar : PubMed/NCBI | |
Moon EJ and Giaccia A: Dual roles of NRF2 in tumor prevention and progression: Possible implications in cancer treatment. Free Radic Biol Med. 79:292–299. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li D, Hong X, Zhao F, Ci X and Zhang S: Targeting Nrf2 may reverse the drug resistance in ovarian cancer. Cancer Cell Int. 21:1162021. View Article : Google Scholar : PubMed/NCBI | |
Cho HY, Kim K, Kim YB, Kim H and No JH: Expression patterns of Nrf2 and keap1 in ovarian cancer cells and their prognostic role in disease recurrence and patient survival. Int J Gynecol Cancer. 27:412–419. 2017. View Article : Google Scholar : PubMed/NCBI | |
Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Kolben T, Burges A, Mahner S, Jeschke U and Trillsch F: Interaction of ERα and NRF2 impacts survival in ovarian cancer patients. Int J Mol Sci. 20:1122018. View Article : Google Scholar : PubMed/NCBI | |
Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, et al: Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 27:211–222. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liew PL, Hsu CS, Liu WM, Lee YC, Lee YC and Chen CL: Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Int J Clin Exp Pathol. 8:5642–5649. 2015.PubMed/NCBI | |
Mizuno T, Suzuki N, Makino H, Furui T, Morii E, Aoki H, Kunisada T, Yano M, Kuji S, Hirashima Y, et al: Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol. 137:299–305. 2015. View Article : Google Scholar : PubMed/NCBI | |
Pylväs-Eerola M, Liakka A, Puistola U, Koivunen J and Karihtala P: Cancer stem cell properties as factors predictive of chemoresistance in neoadjuvantly-treated patients with ovarian cancer. Anticancer Res. 36:3425–3431. 2016.PubMed/NCBI | |
Mata-Greenwood E, Cuendet M, Sher D, Gustin D, Stock W and Pezzuto JM: Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia. 16:2275–2284. 2002. View Article : Google Scholar : PubMed/NCBI | |
Wang XJ, Hayes JD, Henderson CJ and Wolf CR: Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci USA. 104:19589–19594. 2007. View Article : Google Scholar : PubMed/NCBI | |
van der Wijst MG, Huisman C, Mposhi A, Roelfes G and Rots MG: Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion. Mol Oncol. 9:1259–1273. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bollong MJ, Yun H, Sherwood L, Woods AK, Lairson LL and Schultz PG: A small molecule inhibits deregulated NRF2 transcriptional activity in cancer. ACS Chem Biol. 10:2193–2198. 2015. View Article : Google Scholar : PubMed/NCBI | |
Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, Nimmagadda S, Sudini K, Brimacombe KR, Gajghate S, et al: Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 11:3214–3225. 2016. View Article : Google Scholar : PubMed/NCBI | |
Choi EJ, Jung BJ, Lee SH, Yoo HS, Shin EA, Ko HJ, Chang S, Kim SY and Jeon SM: A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. Oncogene. 36:5285–5295. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lin Y, Sui LC, Wu RH, Ma RJ, Fu HY, Xu JJ, Qiu XH and Chen L: Nrf2 inhibition affects cell cycle progression during early mouse embryo development. J Reprod Dev. 64:49–55. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lee YJ, Kim WI, Bae JH, Cho MK, Lee SH, Nam HS, Choi IH and Cho SW: Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways. Ann Surg Treat Res. 98:159–167. 2020. View Article : Google Scholar : PubMed/NCBI | |
Xu Y, Yang Y, Huang Y, Ma Q, Shang J, Guo J, Cao X, Wang X and Li M: Inhibition of Nrf2/HO-1 signaling pathway by dextran sulfate suppresses angiogenesis of gastric cancer. J Cancer. 12:1042–1060. 2021. View Article : Google Scholar : PubMed/NCBI | |
Bovilla VR, Kuruburu MG, Bettada VG, Krishnamurthy J, Sukocheva OA, Thimmulappa RK, Shivananju NS, Balakrishna JP and Madhunapantula SV: Targeted inhibition of anti-inflammatory regulator Nrf2 results in breast cancer retardation in vitro and in vivo. Biomedicines. 9:11192021. View Article : Google Scholar : PubMed/NCBI | |
Van der Wijst MG, Brown R and Rots MG: Nrf2, the Master Redox Switch: The Achilles' heel of ovarian cancer? Biochim Biophys Acta. 1846:494–509. 2014.PubMed/NCBI | |
Benhar M, Shytaj IL, Stamler JS and Savarino A: Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest. 126:1630–1639. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jang BI, Li Y, Graham DY and Cen P: The Role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer. Gut Liver. 5:397–405. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nagano O, Okazaki S and Saya H: Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 32:5191–5198. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ogihara K, Kikuchi E, Okazaki S, Hagiwara M, Takeda T, Matsumoto K, Kosaka T, Mikami S, Saya H and Oya M: Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer Sci. 110:1431–1441. 2019. View Article : Google Scholar : PubMed/NCBI | |
Jogo T, Oki E, Nakanishi R, Ando K, Nakashima Y, Kimura Y, Saeki H, Oda Y, Maehara Y and Mori M: Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation. Gastric Cancer. 24:1089–1099. 2021. View Article : Google Scholar : PubMed/NCBI | |
Sato S, Miyauchi M, Kato M, Kitajima S, Kitagawa S, Hiraoka M, Kudo Y, Ogawa I and Takata T: Upregulated CD44v9 expression inhibits the invasion of oral squamous cell carcinoma cells. Pathobiology. 71:171–175. 2004. View Article : Google Scholar : PubMed/NCBI | |
Miwa T, Nagata T, Kojima H, Sekine S and Okumura T: Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer. Int J Oncol. 51:771–780. 2017. View Article : Google Scholar : PubMed/NCBI | |
Sato S, Miyauchi M, Takekoshi T, Zhao M, Kudo Y, Ogawa I, Kitagawa S, Fujita M and Takata T: Reduced expression of CD44 variant 9 is related to lymph node metastasis and poor survival in squamous cell carcinoma of tongue. Oral Oncol. 36:545–549. 2000. View Article : Google Scholar : PubMed/NCBI | |
Umeda T, Ishida M, Murata S, Mori T, Kawai Y, Itoi N, Tomida K, Tanaka A, Sakai S, Kitamura M, et al: Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: Comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer. 23:869–875. 2016. View Article : Google Scholar : PubMed/NCBI | |
Yasui W, Kudo Y, Naka K, Fujimoto J, Ue T, Yokozaki H and Tahara E: Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: Relation to the proliferation and progression. Int J Oncol. 12:1253–1258. 1998.PubMed/NCBI | |
Okano K, Shimoda T and Matsumura Y: Clinicopathologic and immunohistochemical study of early colorectal cancer with liver metastases. J Gastroenterol. 34:334–340. 1999. View Article : Google Scholar : PubMed/NCBI | |
Koyama S, Maruyama T and Adachi S: Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: A two-color flow-cytometric analysis. J Cancer Res Clin Oncol. 125:47–54. 1999. View Article : Google Scholar : PubMed/NCBI | |
Goi T, Koneri K, Katayama K, Hirose K and Yamaguchi A: Evaluation of clinicopathological factors and the correlation between the adhesion molecule CD44 variant 9 expression and pulmonary metastases from colorectal cancers. Int Surg. 87:130–136. 2002.PubMed/NCBI | |
Bánkfalvi A, Krassort M, Buchwalow IB, Végh A, Felszeghy E and Piffkó J: Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol. 198:343–351. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kakehashi A, Ishii N, Sugihara E, Gi M, Saya H and Wanibuchi H: CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma. Cancer Sci. 107:609–618. 2016. View Article : Google Scholar : PubMed/NCBI | |
Go SI, Ko GH, Lee WS, Lee JH, Jeong SH, Lee YJ, Hong SC and Ha WS: The use of CD44 Variant 9 and Ki-67 combination can predicts prognosis better than their single use in early gastric cancer. Cancer Res Treat. 51:1411–1419. 2019. View Article : Google Scholar : PubMed/NCBI | |
Suwannakul N, Ma N, Midorikawa K, Oikawa S, Kobayashi H, He F, Kawanishi S and Murata M: CD44v9 induces stem cell-like phenotypes in human cholangiocarcinoma. Front Cell Dev Biol. 8:4172020. View Article : Google Scholar : PubMed/NCBI | |
Teal E, Dua-Awereh M, Hirshorn ST and Zavros Y: Role of metaplasia during gastric regeneration. Am J Physiol Cell Physiol. 319:C947–C954. 2020. View Article : Google Scholar : PubMed/NCBI | |
Gout PW, Buckley AR, Simms CR and Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: A new action for an old drug. Leukemia. 15:1633–1640. 2001. View Article : Google Scholar : PubMed/NCBI | |
Thanee M, Loilome W, Techasen A, Sugihara E, Okazaki S, Abe S, Ueda S, Masuko T, Namwat N, Khuntikeo N, et al: CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment. Cancer Sci. 107:991–1000. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, Nakamura T, Abe M, Masuda A, Sakaue T, et al: High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. Cancer Sci. 109:2801–2810. 2018. View Article : Google Scholar : PubMed/NCBI | |
He L, He T, Farrar S, Ji L, Liu T and Ma X: Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem. 44:532–553. 2017. View Article : Google Scholar : PubMed/NCBI | |
Lu Z, Wen T, Wang Y, Kan W and Xun G: Peripheral non-enzymatic antioxidants in patients with schizophrenia: A case-control study. BMC Psychiatry. 20:2412020. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Ye ZW, Janssen-Heininger Y, Townsend DM and Tew KD: Development of Telintra as an inhibitor of glutathione S-Transferase P. Handb Exp Pharmacol. 264:71–91. 2021. View Article : Google Scholar : PubMed/NCBI | |
Sprem M, Babić D, Abramić M, Vrhovec I, Skrk J, Milicić D, Ambriović Ristov A, Kalafatić D and Osmak M: Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: Case series. Croat Med J. 42:624–629. 2001.PubMed/NCBI | |
van Gisbergen MW, Cebula M, Zhang J, Ottosson-Wadlund A, Dubois L, Lambin P, Tew KD, Townsend DM, Haenen GR, Drittij-Reijnders MJ, et al: Chemical reactivity window determines prodrug efficiency toward glutathione transferase overexpressing cancer cells. Mol Pharm. 13:2010–2025. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Yang L, Xiang X, Li Z, Qu K and Li K: A panel of three oxidative stress-related genes predicts overall survival in ovarian cancer patients received platinum-based chemotherapy. Aging (Albany NY). 10:1366–1379. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tong X, Zhao J, Zhang Y, Mu P and Wang X: Expression levels of MRP1, GST-pi, and GSK3beta in ovarian cancer and the relationship with drug resistance and prognosis of patients. Oncol Lett. 18:22–28. 2019.PubMed/NCBI | |
Ferrandina G, Scambia G, Damia G, Tagliabue G, Fagotti A, Benedetti Panici P, Mangioni C, Mancuso S and D'Incalci M: Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome. Ann Oncol. 8:343–350. 1997. View Article : Google Scholar : PubMed/NCBI | |
De Luca A, Pellizzari Tregno F, Sau A, Pastore A, Palumbo C, Alama A, Cicconi R, Federici G and Caccuri AM: Glutathione S-transferase P1-1 as a target for mesothelioma Treatment. Cancer Sci. 104:223–230. 2013. View Article : Google Scholar : PubMed/NCBI | |
Oommen D, Yiannakis D and Jha AN: BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin. Mutat Res. 784–785. 8–15. 2016.PubMed/NCBI | |
Lyttle MH, Satyam A and Hocker MD: Glutathione-S-transferase activates novel alkylating agents. J Med Chem. 37:1501–1507. 1994. View Article : Google Scholar : PubMed/NCBI | |
Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL and Bast RC Jr: Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 3:92010. View Article : Google Scholar : PubMed/NCBI | |
Tew KD, Manevich Y, Grek C, Xiong Y, Uys J and Townsend DM: The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. Free Radic Biol Med. 51:299–313. 2011. View Article : Google Scholar : PubMed/NCBI | |
Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, et al: Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 20:772–780. 2010. View Article : Google Scholar : PubMed/NCBI | |
Dourado DF, Fernandes PA, Ramos MJ and Mannervik B: Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry. 52:8069–8078. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chandrasekaran A and Elias KM: Synthetic lethality in ovarian cancer. Mol Cancer Ther. 20:2117–2128. 2021. View Article : Google Scholar : PubMed/NCBI | |
Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, et al: Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer. 23:1603–1611. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kyo S, Ishikawa N, Nakamura K and Nakayama K: The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies. Cancer Med. 9:421–431. 2020. View Article : Google Scholar : PubMed/NCBI | |
Liu Y, Qiang W, Xu X, Dong R, Karst AM, Liu Z, Kong B, Drapkin RI and Wei JJ: Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget. 6:38983–38998. 2015. View Article : Google Scholar : PubMed/NCBI | |
Scutiero G, Iannone P, Bernardi G, Bonaccorsi G, Spadaro S, Volta CA, Greco P and Nappi L: Oxidative stress and endometriosis: A systematic review of the literature. Oxid Med Cell Longev. 2017:72652382017. View Article : Google Scholar : PubMed/NCBI | |
Sugimoto S, Uchiyama T, Kawahara N, Ohbayashi C and Kobayashi H: Immunohistochemical expression status of p53, CD44v9, and Ki-67 in a series of fallopian tube lesions of High-grade Serous Carcinoma. Int J Gynecol Pathol. 40:419–426. 2021. View Article : Google Scholar : PubMed/NCBI | |
Jiang Z, Fletcher NM, Ali-Fehmi R, Diamond MP, Abu-Soud HM, Munkarah AR and Saed GM: Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecol Oncol. 122:418–423. 2011. View Article : Google Scholar : PubMed/NCBI | |
Khalil HS, Goltsov A, Langdon SP, Harrison DJ, Bown J and Deeni Y: Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells. J Biotechnol. 202:12–30. 2015. View Article : Google Scholar : PubMed/NCBI | |
Worley BL, Kim YS, Mardini J, Zaman R, Leon KE, Vallur PG, Nduwumwami A, Warrick JI, Timmins PF, Kesterson JP, et al: GPx3 supports ovarian cancer progression by manipulating the extracellular redox environment. Redox Biol. 25:1010512019. View Article : Google Scholar : PubMed/NCBI | |
Agnani D, Camacho-Vanegas O, Camacho C, Lele S, Odunsi K, Cohen S, Dottino P and Martignetti JA: Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. J Ovarian Res. 4:182011. View Article : Google Scholar : PubMed/NCBI | |
Jia W, Chen P and Cheng Y: PRDX4 and its roles in various cancers. Technol Cancer Res Treat. 18:15330338198643132019. View Article : Google Scholar : PubMed/NCBI | |
Martinez VD, Vucic EA, Thu KL, Pikor LA, Hubaux R and Lam WL: Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer. Biomed Res Int. 2014:1594592014. View Article : Google Scholar : PubMed/NCBI | |
Hu Y, Rosen DG, Zhou Y, Feng L, Yang G and Liu J: Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: Role in cell proliferation and response to oxidative stress. J Biol Chem. 280:39485–39492. 2005. View Article : Google Scholar : PubMed/NCBI | |
Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK and Rosen EM: BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 64:7893–7909. 2004. View Article : Google Scholar : PubMed/NCBI | |
Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y and Wang J: PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 42:1019282021. View Article : Google Scholar : PubMed/NCBI | |
Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B and Dou QP: The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat. 9:263–273. 2006. View Article : Google Scholar : PubMed/NCBI | |
Shafabakhsh R and Asemi Z: Quercetin: A natural compound for ovarian cancer treatment. J Ovarian Res. 12:552019. View Article : Google Scholar : PubMed/NCBI | |
Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Anticancer efficacy of polyphenols and their combinations. Nutrients. 8:5522016. View Article : Google Scholar : PubMed/NCBI | |
Tendulkar S and Dodamani S: Chemoresistance in ovarian cancer: Prospects for new drugs. Anticancer Agents Med Chem. 21:668–678. 2021. View Article : Google Scholar : PubMed/NCBI | |
Rogers LC, Davis RR, Said N, Hollis T and Daniel LW: Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy. Redox Biol. 15:380–386. 2018. View Article : Google Scholar : PubMed/NCBI | |
Nauman G, Gray JC, Parkinson R, Levine M and Paller CJ: Systematic review of intravenous ascorbate in cancer clinical trials. Antioxidants (Basel). 7:892018. View Article : Google Scholar : PubMed/NCBI | |
Bulavin DV and Fornace AJ Jr: p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res. 92:95–118. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhang P, Hong J, Yoon IN, Kang JK, Hwang JS and Kim H: Clostridium difficile Toxin A induces reactive oxygen species production and p38 MAPK activation to exert cellular toxicity in neuronal cells. J Microbiol Biotechnol. 27:1163–1170. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Huang C, Li J, Leonard SS, Lanciotti R, Butterworth L and Shi X: Vanadate-induced cell growth regulation and the role of reactive oxygen species. Arch Biochem Biophys. 392:311–320. 2001. View Article : Google Scholar : PubMed/NCBI | |
Hemachandra LP, Shin DH, Dier U, Iuliano JN, Engelberth SA, Uusitalo LM, Murphy SK and Hempel N: Mitochondrial superoxide dismutase has a protumorigenic role in ovarian clear cell carcinoma. Cancer Res. 75:4973–4984. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L and Wiman KG: Targeting of Mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 6:212016. View Article : Google Scholar : PubMed/NCBI | |
Wei D, Yu Y, Zhang X, Wang Y, Chen H, Zhao Y, Wang F, Rong G, Wang W, Kang X, et al: Breaking the intracellular redox balance with diselenium nanoparticles for maximizing chemotherapy efficacy on patient-derived xenograft models. ACS Nano. Dec 7–2020.(Epub ahead of print). View Article : Google Scholar | |
Xu Y, Gao W, Zhang Y, Wu S, Liu Y, Deng X, Xie L, Yang J, Yu H, Su J and Sun L: ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int J Oncol. 53:1055–1068. 2018.PubMed/NCBI | |
Liu M, Wang D, Luo Y, Hu L, Bi Y, Ji J, Huang H, Wang G, Zhu L, Ma J, et al: Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis. Cell Death Dis. 12:1892021. View Article : Google Scholar : PubMed/NCBI | |
Müller MF, Florian S, Pommer S, Osterhoff M, Esworthy RS, Chu FF, Brigelius-Flohé R and Kipp AP: Deletion of glutathione peroxidase-2 inhibits azoxymethane-induced colon cancer development. PLoS One. 8:e720552013. View Article : Google Scholar : PubMed/NCBI | |
Krehl S, Loewinger M, Florian S, Kipp AP, Banning A, Wessjohann LA, Brauer MN, Iori R, Esworthy RS, Chu FF and Brigelius-Flohé R: Glutathione peroxidase-2 and selenium decreased inflammation and tumors in a mouse model of inflammation-associated carcinogenesis whereas sulforaphane effects differed with selenium supply. Carcinogenesis. 33:620–628. 2012. View Article : Google Scholar : PubMed/NCBI | |
Li J, Wang Q, Yang Y, Lei C, Yang F, Liang L, Chen C, Xia J, Wang K and Tang N: GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway. J Exp Clin Cancer Res. 38:4382019. View Article : Google Scholar : PubMed/NCBI | |
Taguchi K and Yamamoto M: The KEAP1-NRF2 system as a molecular target of cancer treatment. Cancers (Basel). 13:462020. View Article : Google Scholar : PubMed/NCBI | |
Glasauer A and Chandel NS: Targeting antioxidants for cancer therapy. Biochem Pharmacol. 92:90–101. 2014. View Article : Google Scholar : PubMed/NCBI |